TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Tactile Systems Technology, Inc. NASDAQ:TCMD Healthcare · Medical - Devices
CLOSED · Nov 6 $26.03 CLOSED · Nov 6 Prev close $26.37 Close $26.03 0.00% AH close $26.03 VOL 192K $ Vol $5M RVOL 0.83x
Mkt Cap $589.64M
VOL 192K sh
$ Vol $5M
RVOL 0.83×
Press Release ⚠ 3
Tactile Systems Technology, Inc. Reports Third Quarter 2026 Financial Results
Tactile Medical posted Q3 2026 revenue of $91.9 million, up 7% YoY, led by 13% growth in the core lymphedema line to $81.8 million.
Gross margin expanded to 77%, but GAAP net income fell to $7.2 million ($0.31 diluted EPS) from $8.2 million ($0.36) as operating expenses grew 13%, and airway clearance revenue dropped 25% on the AffloVest transition.
Management reaffirmed FY2026 revenue guidance of $360-366 million and raised Adjusted EBITDA guidance to $50-52 million from $49-51 million, while repurchasing $6.2 million of stock in the quarter.
The company also received expanded FDA 510(k) clearance for the LymphaTech 3D Scanner, submitted a 510(k) for Flexitouch Pro, and appointed Steve Kiewiet as COO.
• 6d ago AI analysis › Press Release
Tactile Medical to Release Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
Tactile Medical will release its third quarter fiscal 2026 financial results after market close on Monday, November 2, 2026.
Management will host a conference call with Q&A at 5:00 p.m. Eastern Time the same day, with a live webcast on the company's investor relations site.
No financial results or guidance are included in this announcement; it is a scheduling notice only.
• 20d ago AI analysis › Press Release ● Major ⚠ 2
Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results
Tactile Systems Technology reported Q2 2026 revenue of $85.7 million, up 9% year-over-year, driven primarily by growth in its lymphedema product line.
Net income more than doubled to $7.8 million, or $0.34 per diluted share, while Adjusted EBITDA increased 48% to $11.4 million on the back of gross margin expansion to 76%.
The company narrowed its full-year 2026 revenue guidance to $360 million to $366 million to account for temporary inventory management dynamics related to the AffloVest launch, though it reaffirmed its Adjusted EBITDA outlook.
Operational highlights included the commercial launch of the next-generation AffloVest system, an exclusive U.S. distribution agreement for MyoSleeve, and $5.3 million in share repurchases.
• 2mo ago AI analysis › Press Release
Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
Tactile Medical announced it will release its fiscal second quarter 2026 financial results after the market closes on August 10, 2026.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the quarterly results.
A live webcast and replay of the call will be available on the investor relations section of the company's website.
• 3mo ago AI analysis › Press Release
Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients
Tactile Medical entered an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve wearable compression device, specifically targeting VA and DoD patients.
The transaction includes a $3 million upfront payment and minimum purchase obligations, adding a new treatment option for earlier-stage chronic swelling to Tactile’s portfolio.
MyoSleeve is an FDA 510(k)-cleared, battery-powered device using electroactive polymer technology, designed to be worn under clothing during daily activities.
• 3mo ago AI analysis › Press Release
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Tactile Medical has fully launched its next-generation AffloVest high-frequency chest wall oscillation therapy system.
The upgraded system retains its existing indications for cystic fibrosis and bronchiectasis but adds enhanced patient comfort, easier setup, and connected care capabilities via Wi-Fi and Bluetooth.
Management highlights that the launch ahead of the winter respiratory season aims to improve long-term therapy adherence and provide clinicians with real-world usage data.
• 5mo ago AI analysis › Press Release
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical announced that management will present at the William Blair 46th Annual Growth Stock Conference.
The presentation is scheduled for Tuesday, June 2, 2026, at 9:20 a.m. Central Time in Chicago.
A live audio webcast will be available on the company's investor relations website, with an archive replay following the event.
• 5mo ago AI analysis › Press Release ● Major
Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results
Tactile Medical reported Q1 revenue of $75.3 million, up 23% year-over-year, driven by broad-based growth across its lymphedema and airway clearance product lines.
The company achieved positive Adjusted EBITDA of $3.7 million compared to a loss in the prior year, prompting a modest raise in full-year 2026 revenue guidance to $360 million-$368 million.
Additionally, the company received FDA 510(k) clearance for its next-generation AffloVest device and repurchased $1.1 million of stock during the quarter.
• 6mo ago AI analysis › 
